OBJECTIVE: The aim was to describe a case of hypersensitivity to rabbit antithymocyte globulin (rATG) occurring in the context of islet transplantation. METHODS: A 36-year-old woman with type 1 diabetes was admitted for islet transplantation. rATG was administered the first day (1.5 mg/kg) with methylprednisolone (2 mg/kg), and on the second day (1.5 mg/kg) without glucocorticoid to avoid potential toxicity to the anticipated islet transplant. RESULTS: At the end of the rATG infusion on the second day she developed hives over her face, chest, and back and tender erythema at her intravenous site (Arthus reaction). Islet transplantation was not performed. She reported exposure to a pet rabbit for 2 years in childhood. Overnight, fever developed and the rash evolved into an erythematous morbilliform eruption affecting the torso. Serum high-sensitivity C-reactive protein (hsCRP) and the erythrocyte sedimentation rate (ESR) were elevated; serum complements C3 and C4 were normal. She received prednisone (50 mg) with subsequent resolution of the rash. Nine days after her initial reaction, she developed a recurrence of the rash and fever with arthralgias; levels of C3 and C4 had fallen. Methylprednisolone (125 mg, twice) was required for symptom improvement, and was gradually tapered as prednisone over the next 4 weeks with resolution of the complement, ESR, and hsCRP abnormalities. Five months after the initial attempt at islet transplantation, she returned to receive 7,879 IE/kg via portal vein infusion under basiliximab, etanercept, tacrolimus, and sirolimus immunosuppression and has required no to low-dose (0.1 U/kg/d) insulin to maintain near-normal glycemic control for > 12 months after transplantation. CONCLUSIONS: Our patient's initial hypersensitivity reaction to rATG was followed by immune-complex type 3 hypersensitivity (serum sickness) requiring high-dose glucocorticoids. Canceling the initial islet infusion proved to be wise, and the patient subsequently did well with islet transplantation under an alternative induction agent.
OBJECTIVE: The aim was to describe a case of hypersensitivity to rabbit antithymocyte globulin (rATG) occurring in the context of islet transplantation. METHODS: A 36-year-old woman with type 1 diabetes was admitted for islet transplantation. rATG was administered the first day (1.5 mg/kg) with methylprednisolone (2 mg/kg), and on the second day (1.5 mg/kg) without glucocorticoid to avoid potential toxicity to the anticipated islet transplant. RESULTS: At the end of the rATG infusion on the second day she developed hives over her face, chest, and back and tender erythema at her intravenous site (Arthus reaction). Islet transplantation was not performed. She reported exposure to a pet rabbit for 2 years in childhood. Overnight, fever developed and the rash evolved into an erythematous morbilliform eruption affecting the torso. Serum high-sensitivity C-reactive protein (hsCRP) and the erythrocyte sedimentation rate (ESR) were elevated; serum complements C3 and C4 were normal. She received prednisone (50 mg) with subsequent resolution of the rash. Nine days after her initial reaction, she developed a recurrence of the rash and fever with arthralgias; levels of C3 and C4 had fallen. Methylprednisolone (125 mg, twice) was required for symptom improvement, and was gradually tapered asprednisone over the next 4 weeks with resolution of the complement, ESR, and hsCRP abnormalities. Five months after the initial attempt at islet transplantation, she returned to receive 7,879 IE/kg via portal vein infusion under basiliximab, etanercept, tacrolimus, and sirolimus immunosuppression and has required no to low-dose (0.1 U/kg/d) insulin to maintain near-normal glycemic control for > 12 months after transplantation. CONCLUSIONS: Our patient's initial hypersensitivity reaction to rATG was followed by immune-complex type 3 hypersensitivity (serum sickness) requiring high-dose glucocorticoids. Canceling the initial islet infusion proved to be wise, and the patient subsequently did well with islet transplantation under an alternative induction agent.
Authors: Andrew L Lundquist; Ravi S Chari; James H Wood; Geraldine G Miller; Heidi M Schaefer; David S Raiford; Kelly J Wright; D Lee Gorden Journal: Liver Transpl Date: 2007-05 Impact factor: 5.799
Authors: Bernhard J Hering; Raja Kandaswamy; Jeffrey D Ansite; Peter M Eckman; Masahiko Nakano; Toshiya Sawada; Ippei Matsumoto; Sung-Hee Ihm; Hui-Jian Zhang; Jamen Parkey; David W Hunter; David E R Sutherland Journal: JAMA Date: 2005-02-16 Impact factor: 56.272
Authors: M D Bellin; R Kandaswamy; J Parkey; H-J Zhang; B Liu; S H Ihm; J D Ansite; J Witson; P Bansal-Pakala; A N Balamurugan; K K Papas; K Papas; D E R Sutherland; A Moran; B J Hering Journal: Am J Transplant Date: 2008-09-19 Impact factor: 8.086
Authors: Bekir Tanriover; Peale Chuang; Bernard Fishbach; J Harold Helderman; Tarik Kizilisik; William Nylander; David Shaffer; Anthony J Langone Journal: Transplantation Date: 2005-07-27 Impact factor: 4.939
Authors: A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Raghavender Boothpur; Karen L Hardinger; Rebecca M Skelton; Brunilda Lluka; Matthew J Koch; Brent W Miller; Niraj M Desai; Daniel C Brennan Journal: Am J Kidney Dis Date: 2009-07-23 Impact factor: 8.860
Authors: R B Stevens; L E Wrenshall; C D Miles; A C Farney; T Jie; J P Sandoz; T H Rigley; A Osama Gaber Journal: Am J Transplant Date: 2016-03-07 Impact factor: 8.086
Authors: Michael R Rickels; Chengyang Liu; Richard D Shlansky-Goldberg; Scott A Soleimanpour; Kumar Vivek; Malek Kamoun; Zaw Min; Eileen Markmann; Maral Palangian; Cornelia Dalton-Bakes; Carissa Fuller; Allen J Chiou; Clyde F Barker; Eline T Luning Prak; Ali Naji Journal: Diabetes Date: 2013-04-29 Impact factor: 9.461